Prediction of cancer drug resistance and implications for personalized medicine

Frontiers in Oncology

Volumn 5, Issue DEC, 2015, Pages

  Volm, Manfred ^a   Efferth, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Drug resistance; Individualized therapy; Survival times

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOPODOZIDE; PROCARBAZINE; TRIAZIQUONE; VINCRISTINE; VINDESINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CHEMOSENSITIVITY; DRUG SENSITIVITY; GENE THERAPY; HUMAN; HYPERTHERMIA; IMMUNOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PERSONALIZED MEDICINE; TREATMENT RESPONSE;

EID: 84954539516     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00282     Document Type: Article

References (103)

1. Pinedo HM, Giaccone G. Drug Resistance in the Treatment of Cancer. Cambridge: Cambridge University Press (1998).
2. Volm M, Mattern J. Resistance mechanisms and their regulation in lung cancer. Crit Rev Oncog (1996) 7(3-4):227-44. doi:10.1615/CritRevOncog.v7.i3-4.50.
3. Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology (2008) 81(4):275-300. doi:10.1159/000115967.
4. Lippert TH, RuoffHJ, Volm M. Could a revision of the current guidelines for cancer drug use improve the quality of cancer treatment? Ther Clin Risk Manag (2014) 10:69-72. doi:10.2147/tcrm.s51404.
5. Mattern J, Volm M. Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treat Rev (1982) 9(4):267-98. doi:10.1016/S0305-7372(82)80041-8.
6. Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol (2007) 35(2):185-97. doi:10.1007/BF02686104.
7. Volm M, Mattern J, Wayss K. The effects of cytostatic drugs on transplanted tumours. An investigation of the correlation between in vivo and in vitro results. Arch Geschwulstforsch (1974) 43(2):137-44.
8. Volm M, Wayss K, Kaufmann M, Mattern J. Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer (1979) 15(7):983-93. doi:10.1016/0014-2964(79)90282-2.
9. Volm M, Lindner C. Detection of induced resistance in short-term-tests. Adriamycin-resistant sarcoma 180. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol (1978) 91(1):1-10. doi:10.1007/BF00305966.
10. Volm M, Maas E, Mattern J. Detection of induced resistance to cytosine-arabinoside with a short-term test. Eur J Cancer (1980) 16(5):733-6. doi:10.1016/0014-2964(80)90216-9.
11. Volm M, Kleine W, Pfleiderer A. Flow-cytometric prognostic factors for the survival of patients with ovarian carcinoma: a 5-year follow-up study. Gynecol Oncol (1989) 35(1):84-9. doi:10.1016/0090-8258(89)90018-8.
12. Volm M, Maas E, Mattern J. In vivo and in vitro detection of induced resistance to daunorubicin in murine leukemia L 1210. Arzneimittelforschung (1981) 31(2):300-2.
13. Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res (1975) 35(10):2619-30.
14. Volm M, Hahn EW, Mattern J, Muller T, Vogt-Moykopf I, Weber E. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res (1988) 48(10):2923-8.
15. Cooperative Study Group for sensitivity Testing of Tumors (Goerttler K, Mattern J, Volm M, et al). In vitro short-term test to determine the resistance of human tumors to chemotherapy: group for sensitivity testing of tumors (KSST). Cancer (1981) 48(10):2127-35.
16. Volm M, Drings P, Hahn EW, Mattern J. Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test. Br J Cancer (1988) 57(2):198-200. doi:10.1038/bjc.1988.42.
17. Alberts DS, Samon SE, Chen HS, Surwit EA, Soehnlen B, Young L, et al. In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet (1980) 2(8190):340-2. doi:10.1016/S0140-6736(80)90340-2.
18. Khoo SK, Hurst T, Webb MJ, Dickie G, Kearsley J, Parsons PG, et al. Clinical value of in vitro drug sensitivity testing based on short-term effects on DNA and RNA metabolism in ovarian cancer. J Surg Oncol (1989) 41(3):201-5. doi:10.1002/jso.2930410314.
19. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst (1990) 82(7):582-8. doi:10.1093/jnci/82.7.582.
20. Blackman KE, Fingert HJ, Fuller AF, Meitner PA. The fluorescent cytoprint assay in gynecological malignancies and breast cancer. Methodology and results. Contrib Gynecol Obstet (1994) 19:53-63.
21. Federico M, Alberts DS, Garcia DJ, Emerson J, Fanta P, Liu R, et al. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome. Gynecol Oncol (1994) 55(3 Pt 2):S156-63. doi:10.1006/gyno.1994.1356.
22. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res (1995) 55(22):5276-82.
23. Csoka K, Tholander B, Gerdin E, de la Torre M, Larsson R, Nygren P. In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer (1997) 72(6):1008-12. doi:10.1002/(SICI)1097-0215(19970917)72:6<1008::AID-IJC15>3.0.CO;2-0.
24. Taylor CG, Sargent JM, Elgie AW, Reid FD, Alton PA, Hill JG. The clinical relevance of chemosensitivity testing in ovarian cancer. Cancer Detect Prev (1998) 22(4):305-12. doi:10.1046/j.1525-1500.1998.CDOA39.x.
25. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol (2000) 77(2):258-63. doi:10.1006/gyno.2000.5728.
26. Taylor CG, Sargent JM, Elgie AW, Williamson CJ, Lewandowicz GM, Chappatte O, et al. Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynaecol Oncol (2001) 22(4):278-82.
27. Hetland TE, Kaern J, Skrede M, Sandstad B, Trope C, Davidson B, et al. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index. Cancer Chemother Pharmacol (2012) 69(5):1307-14. doi:10.1007/s00280-012-1835-9.
28. Neubauer H, Stefanova M, Solomayer E, Meisner C, Zwirner M, Wallwiener D, et al. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res (2008) 28(2A):949-55.
29. Arienti C, Tesei A, Verdecchia GM, Framarini M, Virzi S, Grassi A, et al. Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. Clin Colorectal Cancer (2013) 12(2):122-7. doi:10.1016/j.clcc.2012.11.006.
30. Daidone MG, Silvestrini R, Sanfilippo O, Zaffaroni N, Varini M, De Lena M. Reliability of an in vitro short-term assay to predict the drug sensitivity of human breast cancer. Cancer (1985) 56(3):450-6. doi:10.1002/1097-0142(19850801)56:3<450::AID-CNCR2820560306>3.0.CO;2-V.
31. Kochli OR, Sevin BU, Averette HE, Haller U. Overview of currently used chemosensitivity test systems in gynecologic malignancies and breast cancer. Contrib Gynecol Obstet (1994) 19:12-23.
32. Elledge RM, Clark GM, Hon J, Thant M, Belt R, Maguire YP, et al. Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer. J Clin Oncol (1995) 13(2):419-23.
33. Xu JM, Song ST, Tang ZM, Liu XQ, Jiang ZF, Zhou L, et al. Evaluation of in vitro chemosensitivity of antitumor drugs using the MTT assay in fresh human breast cancer. Breast Cancer Res Treat (1998) 49(3):251-9. doi:10.1023/A:1006019614543.
34. Xu JM, Song ST, Tang ZM, Jiang ZF, Liu XQ, Zhou L, et al. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat (1999) 53(1):77-85. doi:10.1023/A:1006122912146.
35. Eidtmann H, Jonat W, Maass H. Chemosensibilitätstestung gynäkologischer Tumoren mittels 'Volm'-Test und Stammzell-Assay. New York, NY: Georg Thieme Verlag Stuttgart (1985).
36. Khoo SK, Hurst T, Webb MJ, Mackay EV. Short-term in vitro chemosensitivity testing of tumours of the ovary, cervix and uterus. Measurement of DNA metabolism by 3H thymidine incorporation. Aust N Z J Obstet Gynaecol (1986) 26(4):288-94. doi:10.1111/j.1479-828X.1986.tb01591.x.
37. O'Toole SA, Sheppard BL, McGuinness EP, Gleeson NC, Yoneda M, Bonnar J. The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. Cancer Detect Prev (2003) 27(1):47-54. doi:10.1016/S0361-090X(02)00171-X.
38. Kim JH, Lee KW, Kim YH, Lee KH, Oh do Y, Kim J, et al. Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer. J Korean Med Sci (2010) 25(5):684-90. doi:10.3346/jkms.2010.25.5.684.
39. Kawamura H, Ikeda K, Takiyama I, Terashima M. The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer (1997) 33(6):960-6. doi:10.1016/S0959-8049(97)00075-0.
40. Hirai T, Kawano K, Hirabayashi N, Nishiyama M, Yamashita Y, Mukaida H, et al. A novel in vitro chemosensitivity test using materials collected by endoscopic biopsy. Anticancer Drugs (1991) 2(3):269-74. doi:10.1097/00001813-199106000-00008.
41. Link KH, Aigner KR, Kuehn W, Schwemmle K, Kern DH. Prospective correlative chemosensitivity testing in high-dose intraarterial chemotherapy for liver metastases. Cancer Res (1986) 46(9):4837-40.
42. Link KH, Kornmann M, Butzer U, Leder G, Sunelaitis E, Pillasch J, et al. Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer (2000) 89(2):288-96. doi:10.1002/1097-0142(20000715)89:2<288::AID-CNCR13>3.0.CO;2-O.
43. Tveit KM, Gundersen S, Hoie J, Pihl A. Predictive chemosensitivity testing in malignant melanoma: reliable methodology-ineffective drugs. Br J Cancer (1988) 58(6):734-7. doi:10.1038/bjc.1988.299.
44. Ugurel S, Schadendorf D, Pfohler C, Neuber K, Thoelke A, Ulrich J, et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res (2006) 12(18):5454-63. doi:10.1158/1078-0432.ccr-05-2763.
45. Kitten CM, Von HoffDD, Bennett EV Jr, Trinkle JK, Grover FL. The human tumor clonogenic assay in the treatment of patients with lung cancer. Ann Thorac Surg (1983) 36(4):408-10. doi:10.1016/S0003-4975(10)60478-X.
46. Bertelsen CA, Kern DH, Kaiser LR, Mann BD, Holmes EC, Morton DL. Biopsy of thoracic neoplasms for assay of chemosensitivity. New indication for thoracotomy. Arch Surg (1983) 118(9):1074-6. doi:10.1001/archsurg.1983.01390090058013.
47. Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Ghosh BC, et al. Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst (1990) 82(2):117-24. doi:10.1093/jnci/82.2.117.
48. Kawamura M, Gika M, Abiko T, Inoue Y, Oyama T, Izumi Y, et al. Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST). Cancer Chemother Pharmacol (2007) 59(4):507-13. doi:10.1007/s00280-006-0292-8.
49. Alonso K. Human tumor stem cell assay. A prospective clinical trial. Cancer (1984) 54(11):2475-9.
50. Iwadate Y, Fujimoto S, Yamaura A. Differential chemosensitivity in human intracerebral gliomas measured by flow cytometric DNA analysis. Int J Mol Med (2002) 10(2):187-92.
51. Hwang WS, Chen LM, Huang SH, Wang CC, Tseng MT. Prediction of chemotherapy response in human leukemia using in vitro chemosensitivity test. Leuk Res (1993) 17(8):685-8. doi:10.1016/0145-2126(93)90074-U.
52. Durie BG, Young LA, Salmon SE. Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration. Blood (1983) 61(5):929-34.
53. Sondak VK, Bertelsen CA, Tanigawa N, Hildebrand-Zanki SU, Morton DL, Korn EL, et al. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res (1984) 44(4):1725-8.
54. Wada T, Akiyoshi T, Nakamura Y. A simplified tritiated thymidine incorporation assay for chemosensitivity testing of human tumors. Eur J Cancer Clin Oncol (1988) 24(9):1421-4. doi:10.1016/0277-5379(88)90331-8.
55. Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, et al. An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol (1997) 11(3):449-55.
56. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer (2004) 40(6):802-20. doi:10.1016/j.ejca.2004.01.009.
57. Grigsby PW, Zighelboim I, Powell MA, Mutch DG, Schwarz JK. In vitro chemoresponse to cisplatin and outcomes in cervical cancer. Gynecol Oncol (2013) 130(1):188-91. doi:10.1016/j.ygyno.2013.04.005.
58. Salmon SE, Alberts DS, Durie BG, Meyskens FL, Jones SE, Soehnlen B, et al. Clinical correlations of drug sensitivity in the human tumor stem cell assay. Recent Results Cancer Res (1980) 74:300-5. doi:10.1007/978-3-642-81488-4_36.
59. Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH. Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer (1984) 53(6):1240-5. doi:10.1002/1097-0142(19840315)53:6<1240::AID-CNCR2820530604>3.0.CO;2-Y.
60. Salmon SE. Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep (1984) 68(1):117-25.
61. Kimmel DW, Shapiro JR, Shapiro WR. In vitro drug sensitivity testing in human gliomas. J Neurosurg (1987) 66(2):161-71. doi:10.3171/jns.1987.66.2.0161.
62. Bogden AE, Cobb WR. The subrenal capsule assay (SRCA). Eur J Cancer Clin Oncol (1986) 22(9):1033-6. doi:10.1016/0277-5379(86)90002-7.
63. Von HoffDD, Sandbach JF, Clark GM, Turner JN, Forseth BF, Piccart MJ, et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst (1990) 82(2):110-6. doi:10.1093/jnci/82.2.110.
64. Meitner PA. The fluorescent cytoprint assay: a new approach to in vitro chemosensitivity testing. Oncology (Williston Park) (1991) 5(9):75-81. discussion 81-2, 85, 88.
65. Kondo T, Kubota T, Tanimura H, Yamaue H, Akiyama S, Maehara Y, et al. Cumulative results of chemosensitivity tests for antitumor agents in Japan. Japan Research Society for appropriate cancer chemotherapy. Anticancer Res (2000) 20(4):2389-92.
66. Kobayashi H. Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Recent Results Cancer Res (2003) 161:48-61. doi:10.1007/978-3-642-19022-3_5.
67. Kubota T, Weisenthal L. Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question. Gastric Cancer (2006) 9(2):82-7. doi:10.1007/s10120-006-0366-7.
68. Weisenthal LM, Nygren P. Current status of cell culture drug resistance testing (CCDRT). May (2002). Available from: https://www.researchgate.net/publication/237347352 (retrieved December 8th 2015).
69. Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol (2002) 87(1):8-16. doi:10.1006/gyno.2002.6797.
70. Nakada S, Aoki D, Ohie S, Horiuchi M, Suzuki N, Kanasugi M, et al. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response. Int J Gynecol Cancer (2005) 15(3):445-52. doi:10.1111/j.1525-1438.2005.15307.x.
71. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol (2010) 203(1):e1-6. doi:10.1016/j.ajog.2010.01.059.
72. Jung PS, Kim DY, Kim MB, Lee SW, Kim JH, Kim YM, et al. Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res (2013) 33(3):1029-34.
73. Xu X, Dai H, Zhao Y, Wang Y, Qian Z, Chen X. In vitro chemosensitivity assay of ascites in epithelial ovarian cancer. Eur J Gynaecol Oncol (2013) 34(6):559-64.
74. Isogai A, Nagaya M, Matsuoka H, Watanabe T, Tsukikawa S, Kubota S. A new chemosensitivity assay for ascites tumor cells using a thermoreversible gelation polymer as a culture medium and the observed clinical responses. Eur Surg Res (2007) 39(1):41-50. doi:10.1159/000098439.
75. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, et al. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res (1995) 1(12):1537-43.
76. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res (1995) 1(3):305-11.
77. Abe S, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, et al. Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous and scirrhous gastric cancers. Anticancer Res (1999) 19(5C):4581-6.
78. Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, et al. In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol (2006) 11(6):449-53. doi:10.1007/s10147-006-0618-x.
79. Wu KM, Ghantous H, Birnkrant DB. Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States. Food Chem Toxicol (2008) 46(8):2606-10. doi:10.1016/j.fct.2008.05.029.
80. Kubota T, Otani Y, Furukawa T, Hasegawa H, Watanabe M, Kitajima M. Chemosensitivity testing-present and future in Japan. Recent Results Cancer Res (2003) 161:231-41. doi:10.1007/978-3-642-19022-3_18.
81. Kabeshima Y, Kubota T, Watanabe M, Hasegawa H, Furukawa T, Kitajima M. Clinical usefulness of chemosensitivity test for advanced colorectal cancer. Anticancer Res (2002) 22(5):3033-7.
82. Yamaue H, Tani M, Onishi H, Kinoshita H, Nakamori M, Yokoyama S, et al. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas (2002) 25(4):366-72. doi:10.1097/00006676-200211000-00008.
83. Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, et al. Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer (2008) 99(5):760-7. doi:10.1038/sj.bjc.6604528.
84. Nakamori M, Iwahashi M, Nakamura M, Yamaue H. Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma. J Surg Oncol (2003) 84(1):10-6. doi:10.1002/jso.10286.
85. Doerler M, Hyun J, Venten I, PotthoffA, Bartke U, Serova K, et al. Does chemosensitivity-assay-directed therapy have an influence on the prognosis of patients with malignant melanoma stage IV? A retrospective study of 14 patients with malignant melanoma stage IV. Eur J Med Res (2007) 12(10):497-502.
86. Mollgard L, Tidefelt U, Sundman-Engberg B, Lofgren C, Paul C. In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay. Leuk Res (2000) 24(5):445-52. doi:10.1016/S0145-2126(00)00003-5.
87. Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Meinhardt S, Zintl F, et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res (2008) 14(8):2405-12. doi:10.1158/1078-0432.ccr-07-4525.
88. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta (1988) 948(1):87-128.
89. Volm M. Multidrug resistance and its reversal. Anticancer Res (1998) 18(4C):2905-17.
90. Borst P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol (2012) 2(5):120066. doi:10.1098/rsob.120066.
91. Washtien WL. Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells. Mol Pharmacol (1982) 21(3):723-8.
92. Schimke RT. Gene amplification in cultured animal cells. Cell (1984) 37(3):705-13. doi:10.1016/0092-8674(84)90406-9.
93. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science (1988) 241(4874):1813-5. doi:10.1126/science.3175622.
94. Scanlon KJ, Kashani-Sabet M. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci U S A (1988) 85(3):650-3. doi:10.1073/pnas.85.3.650.
95. Whelan RD, Hosking LK, Townsend AJ, Cowan KH, Hill BT. Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. Cancer Commun (1989) 1(6):359-65.
96. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res (1990) 50(19):6119-29.
97. Volm M, Mattern J, Samsel B. Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers. Br J Cancer (1991) 64(4):700-4. doi:10.1038/bjc.1991.384.
98. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev (1994) 13(2):139-68. doi:10.1007/BF00689633.
99. Koomagi R, Mattern J, Volm M. Up-regulation of resistance-related proteins in human lung tumors with poor vascularization. Carcinogenesis (1995) 16(9):2129-33. doi:10.1093/carcin/16.9.2129.
100. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer (1996) 32A(6):921-6. doi:10.1016/0959-8049(96)00080-9.
101. Volm M, Rittgen W. Cellular predictive factors for the drug response of lung cancer. Anticancer Res (2000) 20(5B):3449-58.
102. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von HoffDD, Somerfield MR. American Society of Clinical Oncology Technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 22(17):3631-8. doi:10.1200/JCO.2004.05.065.
103. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol (2011) 29(24):3328-30. doi:10.1200/jco.2011.36.0354.